Dual‑target antibodies spotlight systemic inequities in cancer care and the global race for profit‑driven biotech
Original framing: “Cancer-fighting antibodies with a one-two punch take aim at tumours” — Nature
Scientifically, bispecific antibodies exploit engineered Fc regions and dual‑binding domains to engage tumor antigens and immune effector cells, offering mechanistic advantages over monospecific agents. Yet, pre‑clinical models often fail to capture tumor heterogeneity and immune microenvironment complexity, leading to translational gaps. Rigorous, open‑access data sharing and reproducibility standards are essential to validate efficacy claims.
Bispecific antibodies illustrate how cutting‑edge biomedical innovation can both advance therapeutic potential and reinforce systemic inequities when divorced from broader social, cultural, and ecological contexts.
Historical cycles of hype, coupled with profit‑centric patent regimes, have repeatedly sidelined marginalized patients and overlooked indigenous insights that could enrich design. By embedding equitable licensing, inclusive trial standards, open‑science practices, and respectful knowledge partnerships, the field can pivot from a narrow market narrative to a globally just health paradigm. Actors ranging from WHO and national regulators to community advocacy groups and traditional healers must coordinate to reshape the trajectory toward accessible, culturally resonant cancer care.